{"id":"optimized-ibuprofen","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Gastrointestinal upset (dyspepsia, nausea)"},{"rate":"3-9","effect":"Abdominal pain"},{"rate":"1-3","effect":"Headache"},{"rate":"1-3","effect":"Dizziness"},{"rate":null,"effect":"Increased cardiovascular risk (with chronic use)"},{"rate":null,"effect":"Renal impairment (with chronic use)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that non-selectively blocks COX-1 and COX-2 enzymes, which catalyze prostaglandin production. By reducing prostaglandins, it suppresses inflammatory responses and pain signaling. The term 'optimized' likely refers to formulation improvements (e.g., faster absorption, improved bioavailability, or reduced GI irritation) rather than a novel mechanism.","oneSentence":"Ibuprofen inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:58:35.781Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Mild to moderate pain"},{"name":"Fever"},{"name":"Inflammation associated with arthritis and musculoskeletal conditions"}]},"trialDetails":[{"nctId":"NCT07017361","phase":"NA","title":"ERAS Program Implementation for MIPD","status":"NOT_YET_RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2025-07-15","conditions":"Pancreaticoduodenectomy, ERAS, Minimally Invasive Surgery","enrollment":140},{"nctId":"NCT02781909","phase":"PHASE2","title":"Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis","status":"COMPLETED","sponsor":"Fundació Institut Germans Trias i Pujol","startDate":"2016-09","conditions":"Tuberculosis","enrollment":24},{"nctId":"NCT00961753","phase":"PHASE4","title":"Safety/Efficacy Study of Optimizing Ibuprofen Dosing to Achieve Higher PDA Closure Rates","status":"TERMINATED","sponsor":"OSF Healthcare System","startDate":"2009-08","conditions":"Patent Ductus Arteriosus","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1110,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["neoprofen"],"phase":"marketed","status":"active","brandName":"optimized ibuprofen","genericName":"optimized ibuprofen","companyName":"OSF Healthcare System","companyId":"osf-healthcare-system","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ibuprofen inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever. Used for Mild to moderate pain, Fever, Inflammation associated with arthritis and musculoskeletal conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}